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Abstract
The ability to induce somatic cells to pluripotency by ectopic expression of defined transcription factors (e.g. KLF-4, OCT4,
SOX2, c-MYC, or KOSM) has transformed the future of regenerative medicine. Here we report somatic cell reprogramming of
human umbilical vein endothelial cells (HUVECs), yielding induced pluripotent stem (iPS) cells with the fastest kinetics, and
one of the highest reprogramming efficiencies for a human somatic cell to date. HUVEC-derived iPS (Huv-iPS) cell colonies
appeared as early as 6 days after a single KOSM infection, and were generated with a 2.5–3% reprogramming efficiency.
Furthermore, when HUVEC reprogramming was performed under hypoxic conditions in the presence of a TGF-beta family
signaling inhibitor, colony formation increased an additional ,2.5-fold over standard conditions. Huv-iPS cells were
indistinguishable from human embryonic stem (ES) cells with regards to morphology, pluripotent marker expression, and
their ability to generate all embryonic germ layers in vitro and in vivo. The high efficiency and rapid kinetics of Huv-iPS cell
formation, coupled with the ease by which HUVECs can be collected, expanded and stored, make these cells an attractive
somatic source for therapeutic application, and for studying the reprogramming process.
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Introduction
Seminal studies demonstrated that fibroblasts could be repro-
grammed to pluripotency by ectopic expression of defined factors
[1–3]. Somatic cell reprogramming has now been performed with
numerous somatic sources with variable kinetics and efficiencies
[4,5]. Among these, recent reports have demonstrated that iPS
cells can be generated from human peripheral blood samples,
advancing practical methods of obtaining patient-specific iPS cells
[6–8]. However, while the accessibility of this somatic cell source
provides an advantage, reprogramming blood samples is not an
efficient (,0.001–0.1%) or rapid (,1 month) process [6–8]. More
importantly, primary blood samples cannot be continually
passaged or easily manipulated, resulting in limited flexibility to
generate iPS cells.
In contrast, human fibroblasts are amenable to culture
manipulations, but are also inefficient (,0.01%) and slow (,1
month) in undergoing reprogramming [2,3]. We therefore sought
to find a more practical cell type that could be readily isolated and
expanded, yet could reprogram quickly and efficiently. Here we
report the rapid reprogramming of HUVECs, with an efficiency
approximately 300-fold higher than human fibroblasts [2,3]. The
methods by which HUVECs can be readily obtained in large
quantities without purification steps [9], coupled with their fast
and efficient rate of reprogramming, makes this somatic cell source
practical for therapeutic application, and for studying the
mechanisms governing reprogramming.
Methods
iPS cell generation
Keratinocytes or HUVECs (Lonza) were infected at similar
passage (generally at p2 or p3) with equivalent ratios of
retroviruses encoding KOSM by spinfection at 800 g for 1 hour
at RT in the presence of polybrene (8 mg/ml). Cells were replated
onto MEFs (Millipore) in their respective media, and switched to
ES cell medium for iPS cell colony formation. Resulting iPS cell
colonies were either manually picked for iPS cell line derivation
(,10–12 days after infection), or stained for Nanog as described
(,14–20 days after infection, to enable iPS cell colony formation
from keratinocyte controls). Reprogramming efficiencies were then
determined by calculating the number of Nanog positive colonies
as a percentage of GFP positive cells. For reprogramming
experiments performed in hypoxic conditions, cells were placed
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19743in 5% 02 incubators 4 days after the initial infection (i.e. when the
cells were switched to ES cell medium) where they remained for
the duration of the assay. For TGF-beta family signaling inhibitor
reprogramming experiments, cells were treated daily with 10 mM
SB431532 (Sigma) from day 4 to day 10 after the initial infection,
and then were treated with ES cell media without SB431532 for
the duration of the assay.
Cell lines and culture
Human neonatal keratinocytes (Lonza) and HUVECs (Lonza)
were grown according to manufacturer’s recommendations. 293T
cells (ATCC) were cultured in DMEM (Invitrogen) containing
10% fetal calf serum (FCS). Human H1 or H9 ES cell lines
(Wicell) were cultured as previously described [10–12]. iPS cell
lines obtained from keratinocytes [13] (KiPS4F2, KiPS4FA,
KiPS4FB), astrocytes [14] (ASTiPS4F5) or fibroblasts [15]
(FiPS4F5) were used as controls, and were all fully characterized
using similar methodologies and criteria as described herein.
Plasmids and virus preparation
The following moloney murine leukemia virus-based retroviral
vectors were obtained from Addgene: pMXs-hOCT4, pMXs-
hSOX2, pMXs-hKLF4 and pMXs-hc-Myc (plasmids 17217,
17218, 17219 and 17220 respectively). pMXs-eGFP was kindly
provided by Dr. Teruhisa Kawamura (Gene Expression Labora-
tory, The Salk Institute, La Jolla, CA). Packaging plasmids
(pCMV-gag-pol-PA and pCMV-VSVg) were kindly provided by
Dr. Gerald Pao, Laboratory of Genetics, The Salk Institute, La
Jolla, CA. Retrovirus was collected 24 hours following cotransfec-
tion of plasmids in 293T cells using Lipofectamine (Invitrogen) in
accordance with manufacturer’s recommendations.
Immunofluorescence and immunohistochemistry
For the immunohistochemical detection of Nanog, cells were
first fixed with 4% formaldehyde in PBS for 15 minutes at room
temperature (RT). Following washing in PBS, cells were incubated
in 0.4% Triton-X100/PBS at RT for 10 minutes. A rabbit anti-
human Nanog antibody (1:500, Abcam) was diluted in PBS
containing 1% BSA (PBS/BSA) and was used for overnight
incubation at 4uC. Cells were then washed in PBS/BSA, and
incubated with a secondary biotin-conjugated anti-rabbit antibody
(1:2000) for an additional 2 hours at RT. After washing in PBS/
BSA, cells were incubated at RT with streptavidin-HRP (Vector,
1:1000) for 2 hours, and a DAB substrate kit for peroxidase
(Vector, SK-4100) was used to develop the staining.
For standard immunofluorescence, cells were fixed and
permeabilized as described, followed by blocking in PBS/BSA
containing 5% FCS for 1 hour at RT. Antibodies to FoxA2
(R&D), Tuj-1 (Covance), alpha smooth muscle actin (ASMA,
Sigma) were diluted in PBS/BSA and used in overnight
incubations at 4uC, followed by incubation with fluorescently-
conjugated secondary antibodies (AlexaFluor 488 or AlexaFluor
568, Invitrogen) for 2 hours at RT. 4,6-Diamidino-2-phenylindole
(DAPI) was used to visualize nuclei at a concentration of 10 mg/ml
in PBS. Additional immunofluorescence, and hematoxylin and
eosin staining, was performed as previously described [13].
Flow cytometry
Cells were collected with TrypLE (Invitrogen), resuspended in
PBS containing 1% BSA (PBS/BSA) and labeled with fluores-
cently conjugated antibodies to Tra-1-60 (BD Pharmingen), Tra-
1-81 (Stemgent), SSEA-4 (BD Pharmingen), CD34 (BD Pharmin-
gen), CD45 (BD Pharmingen), CD31 (BD Pharmingen), or the
appropriate isotype controls. Samples were analyzed by flow
cytometry on a FACScan (Becton-Dickinson), and figures
generated using FlowJo software (TreeStar Inc).
Real-time PCR
To determine gene expression levels, total RNA was first
isolated using Trizol Reagent (Invitrogen), and reverse transcribed
using the SuperScript II Reverse Transcriptase kit (Invitrogen),
according to the manufacturer’s recommendations. Real-time
PCR analysis was performed using the SYBR-Green PCR Master
mix (Applied Biosystems). The expression values of individual
genes were normalized to GAPDH, and are shown relative to
control samples as indicated. See Table 1 for a complete list of
primers.
For the stem cell array analysis between ES cells and the Huv-
iPS cell lines, real-time PCR of a selected number of genes based
on the Human Stem RT2 Cell Array (SuperArray Bioscience
Corporation) was performed. These genes differentially discrim-
inate between pluripotent and somatic cell types. For a detailed
description of the genes and primer sets used for this analysis see
Ruiz et al [14].
In order to determine the copy numbers of transgenes
introduced by reprogramming, a quantitative real-time PCR
Table 1. List of primers.
Primer Sequence (59 to 39) Application
OCT4 total-F GGAGGAAGCTGACAACAATGAAA qPCR
OCT4 total-R GGCCTGCACGAGGGTTT qPCR
SOX2 total-F TGCGAGCGCTGCACAT qPCR
SOX2 total-R TCATGAGCGTCTTGGTTTTCC qPCR
KLF4 total-F CGAACCCACACAGGTGAGAA qPCR
KLF4 total-R GAGCGGGCGGCGAATTTCCAT qPCR
c-MYC total-F AGGGTCAAGTTGGACAGTGTCA qPCR
c-MYC total-R TGGTCGATTTTCGGTTGTTG qPCR
OCT4 end-F GGGTTTTTGGGATTAAGTTCTTCA qPCR
OCT4 end-R GCCCCCACCCTTTGTGTT qPCR
SOX2 end-F CAAAAATGGCCATGCAGGTT qPCR
SOX2 end-R AGTTGGGATCGAACAAAAGCTATT qPCR
KLF4 end-F AGCCTAATTGATGGTGCTTGGT qPCR
KLF4 end-R TTGAAAACTTTGGCTTCCTTGTT qPCR
c-MYC end-F CGGGCGGGCACTTTG qPCR
c-MYC end-R GGAGAGTCGCGTCCTTGCT qPCR
GAPDH-F GGACTCATGACCACAGTCCATGCC qPCR
GAPDH-R TCAGGGATGACCTTGCCCACAG qPCR
OCT4 genomic-F AGCGATCAAGCAGCGACTAT qPCR
OCT4 genomic-R GTGAAGTGAGGGCTCCCATA qPCR
SOX2 genomic-F AACCCCAAGATGCACAACTC qPCR
SOX2 genomic-R GCTTAGCCTCGTCGATGAAC qPCR
KLF4 genomic-F GTCTCTTCGTGCACCCACTT qPCR
KLF4 genomic-R TGCTCAGCACTTCCTCAAGA qPCR
c-MYC genomic-F CCCTCAACGTTAGCTTCACC qPCR
c-MYC genomic-R CAGCAGCTCGAATTTCTTCC qPCR
GAPDH genomic-F ACCCAGAAGACTGTGGATGG qPCR
GAPDH genomic-R TTCAGCTCAGGGATGACCTT qPCR
doi:10.1371/journal.pone.0019743.t001
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numbers of four reprogramming factors (OCT4, SOX2, KLF-4, c-
MYC). Briefly, primer sets specifically detecting the coding
sequence within a single exon were designed for each reprogram-
ming factor, and tested for both ES cell genomic DNA (gDNA)
and reprogramming retroviral vectors. High quality gDNA
samples were prepared using QIAGEN DNeasy Blood & Tissue
Kit (QIAGEN), and measured by NanoDrop 8000 Spectropho-
tometer (Thermo Scientific). For each reaction, 10 ng gDNA from
each sample were run in triplicate along with four points of ES cell
gDNA standard curve templates made by 10-fold serial dilutions
(from 100 ng to 0.1 ng) to ensure adequate amplification efficiency
(.90%). Levels of each reprogramming factor were normalized to
GAPDH for each sample, and calculated relative to the
endogenous levels in ES cells (2 copies of each factor per genome).
The results were presented as means +/2 standard deviations of
both endogenous and transgenic copy numbers. All PCR reactions
were performed using the SYBR-Green PCR Master mix on the
ViiA 7 Real-time PCR system (Applied Biosystems) in accordance
to the manufacturer’s instructions, and were repeated three times.
See Table 1 for a complete list of primers.
In vitro differentiation
For embryoid body (EB) differentiation, ES or Huv-iPS cell
colonies growing on MEFs (Millipore) were loosely detached by
dispase treatment, washed and resuspended in EB media
(DMEM/F12 containing 10% FCS (Atlanta Biologicals),
0.5 mM L-glutamine, 0.1 mM non-essential amino acids and
55 mM b-mercaptoethanol). EBs were maintained on low
attachment plates and replenished daily with fresh EB media.
After 4 days, EBs were plated on gelatin-coated plates, allowed to
differentiate for another 10 days in EB media, fixed and stained as
described.
Teratoma assay and karyotype analysis
To test for teratoma formation, iPS cell lines were injected into
severe combined immunodeficient mice (NOD.Cg-Prkdc
scid
Il2rg
tm1Wjl/SzJ; Jackson Laboratories). Briefly, ,10
6 iPS cells in
Figure 1. Derivation of induced pluripotent cells from HUVECs. HUVECs were retrovirally infected with KLF-4, OCT4, SOX2 and c-MYC (KOSM)
to generate induced pluripotent stem cells (Huv-iPS4F). (A) Schematic representation of the experimental strategy used to reprogram HUVECs. (B)
Infected HUVECs were plated onto mouse embryonic fibroblasts (MEFs) and colony formation assessed. Retroviral transduction of GFP was included
to measure infection efficiency, and monitor silencing of transgenes during reprogramming. Note the appearance of GFP negative colonies with an
ES cell-like morphology as early as 6 days after infection, as demonstrated by tracking an individual colony (black arrow) from day 6 through day 11.
An example of an established Huv-iPS cell line grown in feeder-free conditions is shown on the right. All images were acquired with a standard
microscope using a 206objective; all fluorescent images shown were acquired with the same exposure time.
doi:10.1371/journal.pone.0019743.g001
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or testes of anesthetized mice. Mice were then monitored for
formation of teratomas, and euthanized ,6–12 weeks after
injection. Collected teratomas were analyzed by immunofluores-
cence or hematoxylin and eosin staining as previously described
[13]. All mouse experimental procedures were performed and
approved (accepted protocol number 08–025) by The Salk
Institute Institutional Animal Care and Use Committee (IACUC).
All Huv-iPS cell lines were karyotyped by Wicell.
Statistical analysis
Results are shown as mean values 6 standard deviation (SD) or
standard error of the mean (SEM) as indicated. The values
obtained for the stem cell array were analyzed using the Pearson
Figure 2. Reprogramming of HUVECs is highly efficient. (A) HUVECs and keratinocytes were infected in parallel with retroviruses encoding
KOSM and GFP. Shown are representative histograms of GFP expression for each cell type 3 days after infection, as assessed by flow cytometry. (B)
Equivalent numbers of GFP positive cells were plated on MEFs, and a representative example of immunohistochemical staining (of an individual well
from a 6-well plate) for Nanog of the resulting colonies is shown. MEF feeder layers serve as an internal negative control for Nanog staining. (C)
HUVECs and keratinocytes (Ker) were infected in parallel (a single infection, 1X, or two infections, 2X) plated, and stained for Nanog. Nanog positive
colonies were numerated and plotted as a percentage of GFP positive cells, indicative of reprogramming efficiency. Results were quantified from
triplicate samples, and are representative of at least three independent experiments. Error bars depict the standard error mean (SEM). (D) Equivalent
numbers of KOSM-infected HUVECs (1X infection) were plated and placed in incubators containing 20% O2 (standard conditions) or 5% 02 (hypoxic
conditions) in the presence or absence of the TGF-beta family signaling inhibitor SB431532 (SB). The reprogramming efficiencies relative to controls
are shown. Results were quantified from triplicate samples, and are representative of two independent experiments. Error bars depict the SEM.
*P,0.05.
doi:10.1371/journal.pone.0019743.g002
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statistics were performed using unpaired two-tailed Student’s t-
tests. P values,0.05 were considered statistically significant.
Results
HUVECs were transduced with retroviruses encoding KOSM to
inducesomaticcellreprogramming(Figure1A).Retroviralinfections
with GFP were included to assess infection efficiency,and to monitor
transgene silencing [16]. We observed the appearance of colonies
with an ES cell-like morphology as early as 6 days after two serial
KOSM infections (Figure 1B). In several cases, these colonies were
GFP negative, correlating with transgene silencing (Figure 1B). We
next tested if a single infection would be sufficient to elicit the
production of iPS cells. To assess the efficiency of HUVEC
reprogramming, we performed parallel infection experiments with
keratinocytes, a human somatic cell type with one of the highest
reported reprogramming efficiencies to date [13]. HUVECs and
keratinocytes were infected in parallel with retroviruses encoding
KOSM and GFP on day 0 (1X), or day 0 and day 1 (2X), equivalent
numbers of GFP positive cells plated, and resulting colonies stained
for Nanog as an initial measure of pluripotency (Figure 2A, 2B). We
routinely observed .80% transduction efficiency for all conditions
(Figure 2A). Following a single KOSM infection, HUVECs
displayed a 2.5–3% reprogramming efficiency, whereas keratino-
cytes demonstrated an approximate 1% reprogramming efficiency,
in agreement with our previous findings (Figure 2C) [13].
Interestingly,two serial KOSMinfectionsdecreasedreprogramming
efficiencies for both cell types, although more strikingly for
keratinocytes, and resulted in a more substantial efficiency difference
between HUVECs and keratinocytes (1X=2.5–3 fold difference vs.
2X=7–8 fold difference, respectively; Figure 2C). These results
indicate that the number of infections should be taken into account
when determining reprogramming efficiencies, and suggest that the
balance of viral incorporation and tolerance to infection varies for
somatic cell types. Of note, HUVECs that had undergone additional
freeze/thaws before infection, or had been passaged repeatedly (e.g.
7–8 passages), still generated the high reprogramming efficiencies
indicated (Figure 2C).
Previous studies have demonstrated that hypoxia or inhibition
of TGF-beta family signaling enhances iPS cell generation [17–
19]. We next tested each of these conditions, alone or in
combination, in HUVEC-mediated colony formation. Performing
reprogramming under hypoxic conditions was sufficient to
increase the reprogramming efficiency compared to controls
grown in standard 20% O2 conditions (Figure 2D). However,
treatment with the TGF-beta family signaling inhibitor SB431532
in combination with hypoxic conditions further increased
reprogramming ,2.5-fold over controls (Figure 2D).
To characterize HUVEC-generated colonies, we manually
picked ,12 GFP negative colonies 10–12 days after KOSM
infection, and randomly chose three lines (Huv-iPS4F1, Huv-
iPS4F3, Huv-iPS4F6) for full characterization. We first evaluated
the expression of the reprogramming factors, following the initial
infection, as well as in the established Huv-iPS cell lines generated.
Expression of OCT4, SOX2, KLF-4 and c-MYC was induced at
similar levels following 3 days of infection for both HUVECs and
keratinocytes (Figure 3A). Individual Huv-iPS cell lines also
demonstrated endogenous OCT4, SOX2, KLF-4 and c-MYC gene
expression levels that were similar to ES cell controls, and to the
total (endogenous+transgene) expression levels for each gene
(Figure 3A). Although this is indicative of strong transgene silencing,
minor contribution from transgenes to the total expression of KLF-4
(each line) or c-MYC (Huv-iPS4F3 cell line) was observed
(Figure 3A). Furthermore, Huv-iPS cells showed transgene copy
numbers at comparable levels to other iPS cell lines that had been
generated using the same retroviral approach, but from less efficient
somatic sources such as fibroblasts (FiPS4F5), astrocytes (AS-
TiPS4F5), and keratinocytes (KiPS4F2, KiPS4FA, KiPS4FB)
(Figure 3B) [13–15]. Thus, the higher efficiency of HUVECs to
generate iPS cells is not likely due to differences in infection
efficiency or transgene integration, but to other as of yet
undetermined mechanisms of inducing pluripotency.
We next evaluated pluripotency markers of each Huv-iPS cell
line at the protein level. Cell surface protein marker analysis
demonstrated that Huv-iPS cells expressed the pluripotent markers
Tra-1-60, Tra1-81 and SSEA-4, and had lost expression of the
endothelial marker CD31. Furthermore, the parental HUVEC
populations were negative for CD45 and CD34, ruling out the
contribution of any possible residual hematopoietic cells obtained
from HUVEC preparations in the high reprogramming efficien-
cies observed (Figure 4A). To further assess the overall profile of
Huv-iPS cell lines relative to ES cells, we analyzed the expression
of several genes involved in various aspects of stem cell biology (see
Methods). As shown in Figure 4B, using the Pearson correlation
coefficient to measure the distance between the different sets of
values, individual Huv-iPS cell lines had stem cell gene expression
profiles that were as similar to ES cell controls as individual ES cell
lines were to one another.
As a final stringent analysis of Huv-iPS cell pluripotency, we
evaluated the potential of each Huv-iPS cell line to differentiate
into the three embryonic germ layers in vitro and in vivo.
Immunofluorescence analysis of embryoid bodies differentiated
from Huv-iPS cells showed the presence of markers for endoderm,
ectoderm and mesoderm lineages (Figure 5A). Injection of Huv-
iPS cell lines into immunocompromised mice produced teratomas,
which contained tissues from all three embryonic germ layers
(Figure 5B, 5C). Lastly, Huv-iPS cell lines displayed a normal
karyotype (Figure 5D), and have been maintained in feeder-free
conditions for over 40 passages. These collective results demon-
strate the successful reprogramming of HUVECs into iPS cells,
with the fastest kinetics and one of the highest efficiencies reported
for any human somatic cell to date.
Discussion
Our findings demonstrating rapid and highly efficient repro-
gramming of HUVECs are in contrast to a previous report, which
Figure 3. Reprogramming factor expression and transgene integration in Huv-iPS cells. (A) Gene expression levels of the endogenous
and total levels of OCT4, SOX2, KLF-4 and c-MYC in Huv-iPS cell lines, ES cell controls (H1 and H9 cell lines), somatic cells (keratinocytes and HUVECs) or
somatic cells 3 days after KOSM infection. Individual real-time PCR reactions were normalized to GAPDH, and plotted relative to the expression level in
HUVECs. Data are shown as the relative averages 6 standard deviation (SD). (B) Copy numbers of the four reprogramming factor transgenes (OCT4,
SOX2, KLF-4 and c-MYC) were determined in Huv-iPS cell lines by quantitative real-time PCR as described in Methods. Data were presented as the copy
number of both endogenous gene (2 copies/genome) and transgene (the portion higher than 2 copies/genome) for each reprogramming factor. Two
human ES cell lines (H9, H1; white bars) were used as negative controls for transgenes. The copy numbers of transgenes in three Huv-iPS cell lines
(Huv-iPS4F1, Huv-iPS4F3, Huv-iPS4F6; black bars) were compared to five other characterized iPS cell lines (gray bars) obtained from fibroblasts
(FiPS4F5), astrocytes (ASTiPS4F5) or keratinocytes (KiPS4F2, KiPS4FA, KiPS4FB). Data are shown as the relative averages 6 standard deviation (SD).
doi:10.1371/journal.pone.0019743.g003
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colonies after more than two weeks, with a reprogramming
efficiency that was 100-fold lower (,0.03%) [20]. Very recent
studies also demonstrated that iPS cells could be generated from
HUVECs at ,0.03% efficiency. However, in these reports
reprogramming was performed using only SOX2 and OCT4
[21], or OCT4 and a combination of chemical compounds [22];
thus, the use of fewer factors are likely contributing to the lower
reprogramming efficiencies and delayed kinetics observed in these
instances [21,22].
Although the reasons for some of these discrepancies remain
unclear, variations in somatic cell sources, virus quality and infection
protocols are known variables in reprogramming [16]. However, we
have tested various HUVEC lots and consistently found reprogram-
Figure 4. Huv-iPS cells express pluripotent markers. (A) Flow cytometry analysis for pluripotency (Tra-1-60, Tra-1-81, SSEA-4), hematopoietic
(CD45, CD34) or endothelial (CD31) markers as indicated, for all Huv-iPS cell lines, and the appropriate positive controls (H9 ES cells, hematopoietic
cells, or HUVECs, respectively). Percentages were determined relative to the appropriate isotype control (black lines) for each cell type. (B) Ct values
obtained from real-time PCR analysis of a defined set of genes (see Methods) were normalized to GAPDH expression, and plotted to generate a
graphical representation of the similarity between the different cell lines as indicated. r=Pearson coefficient.
doi:10.1371/journal.pone.0019743.g004
Figure 5. Huv-iPS cell lines demonstrate pluripotency in vitro and in vivo. (A) Huv-iPS cell lines were used in embryoid body (EB)-mediated
differentiation assays, and stained by immunofluorescence for endodermal (FoxA2), ectodermal (Tuj-1), or mesodermal (alpha smooth muscle actin
(ASMA)) markers representing each embryonic germ layer. 4,6-Diamidino-2-phenylindole (DAPI) staining shows nuclei. (B–C) Huv-iPS cell lines were
injected into immunocompromised mice and analyzed for teratoma formation. Resulting teratomas were analyzed for tissues representing each of
the three embryonic germ layers by (B) fluorescent imaging (endodermal markers FoxA2 and a-fetoprotein (AFP), upper panels; ectodermal markers
GFAP and TuJ-1, middle panels; mesodermal markers alpha sarcomeric actin (ASA) and alpha smooth muscle actin (ASMA), lower panels; nuclei are
stained with DAPI or by (C) hematoxlin and eosin staining (endoderm, upper panels; ectoderm, middle panels; or mesoderm, lower panels). All
images for individual lines were obtained from a single tumor, and were acquired using a 406objective. (D) Karyotype analysis demonstrating that
Huv-iPS cell lines maintain normal chromosomal integrity.
doi:10.1371/journal.pone.0019743.g005
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6, and thus it is unlikely that the source of HUVECs is causing these
differences (Figure 2C). Additionally, we performed parallel trans-
duction experiments with human keratinocytes and fibroblasts, and
found that the observed reprogramming efficiencies and kinetics
correlated with what has been previously reported in the literature
(Figure 2C, data not shown) [2,3,13]. Thus, these collective data
indicate that our reprogramming experiments are accurately
assessing the reprogramming capabilities of HUVECs.
Our laboratory and others have reported the generation of iPS
cells from human cord blood [23,24], which provides the
advantage of an available banked HLA-typed somatic cell source
for reprogramming. Furthermore, iPS cells obtained from
embryonic somatic sources have been shown to be safer than
those obtained from adult cells [25], which have been subjected to
mutagenic events during aging. HUVECs are isolated from
newborn’s umbilical cord with no risk to the donor, can be rapidly
prepared without purification steps, and stored in large quantities
[9]. Thus, HUVECs could be collected by cord blood banks, to
serve as an alternative HLA-typed reprogramming source, since a
reasonable amount of HLA-typed iPS cell lines could provide a
beneficial match for a considerable percentage of the population
[26,27]. This would also enable the reserve of valuable cord blood
samples for use in bone marrow transplantation. The rapid and
efficient generation of iPS cells from HUVECs could also provide
an important tool to discern the mechanisms governing repro-
gramming. These combined reasons make HUVECs an attractive
somatic source for therapeutic application, and for studying the
reprogramming process.
Acknowledgments
We gratefully acknowledge Dr. W. Travis Berggren, Margaret Lutz and
Krystal Sousley of The Salk Institute Stem Cell Core for their invaluable
advice and technical support. We thank Drs. Kristen Brennand, Dimi
Bissig, Sheng-Lian Yang, and Jennifer Lin for their helpful assistance in
teratoma analysis, Dr. Ignacio Sancho-Martinez for hematopoietic cell
samples, and Merce Marti, Lola Mulero, Cristina Pardo and Cristina
Morera, for their excellent work at the Histology and Bioimaging
Department of the CMRB. We also thank the members of the Belmonte
laboratory, and Dr. Leanne Jones and the Stem Cell Interest Group, for
helpful discussions, and May Schwarz for dedicated administrative support.
Author Contributions
Conceived and designed the experiments: ADP SR FY JCIB. Performed
the experiments: ADP SR FY AH EMB. Analyzed the data: ADP SR FY
JCIB. Wrote the paper: ADP SR. Financial support: JCIB.
References
1. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from
mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:
663–676.
2. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007)
Induction of pluripotent stem cells from adult human fibroblasts by defined
factors. Cell 131: 861–872.
3. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al.
(2007) Induced pluripotent stem cell lines derived from human somatic cells.
Science 318: 1917–1920.
4. Yamanaka S (2009) A fresh look at iPS cells. Cell 137: 13–17.
5. Yamanaka S, Blau HM (2010) Nuclear reprogramming to a pluripotent state by
three approaches. Nature 465: 704–712.
6. Seki T, Yuasa S, Oda M, Egashira T, Yae K, et al. (2010) Generation of induced
pluripotent stem cells from human terminally differentiated circulating T cells.
Cell Stem Cell 7: 11–14.
7. Loh YH, Hartung O, Li H, Guo C, Sahalie JM, et al. (2010) Reprogramming of
T cells from human peripheral blood. Cell Stem Cell 7: 15–19.
8. Staerk J, Dawlaty MM, Gao Q, Maetzel D, Hanna J, et al. (2010)
Reprogramming of human peripheral blood cells to induced pluripotent stem
cells. Cell Stem Cell 7: 20–24.
9. Baudin B, Bruneel A, Bosselut N, Vaubourdolle M (2007) A protocol for
isolation and culture of human umbilical vein endothelial cells. Nat Protoc 2:
481–485.
10. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, et al.
(1998) Embryonic stem cell lines derived from human blastocysts. Science 282:
1145–1147.
11. Ludwig TE, Bergendahl V, Levenstein ME, Yu J, Probasco MD, et al. (2006)
Feeder-independent culture of human embryonic stem cells. Nat Methods 3:
637–646.
12. Ludwig TE, Levenstein ME, Jones JM, Berggren WT, Mitchen ER, et al. (2006)
Derivation of human embryonic stem cells in defined conditions. Nat Biotechnol
24: 185–187.
13. Aasen T, Raya A, Barrero MJ, Garreta E, Consiglio A, et al. (2008) Efficient and
rapid generation of induced pluripotent stem cells from human keratinocytes.
Nat Biotechnol 26: 1276–1284.
14. Ruiz S, Brennand K, Panopoulos AD, Herrerı ´as A, Gage FH, et al. (2010) High
efficient generation of induced pluripotent stem cells from astrocytes. PLoS ONE
5: 1–9.
15. Liu GH, Barkho BZ, Ruiz S, Diep D, Qu J, et al. (2011) Recapitulation of
premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome.
Nature 472: 221–225.
16. Maherali N, Hochedlinger K (2008) Guidelines and techniques for the
generation of induced pluripotent stem cells. Cell Stem Cell 3: 595–605.
17. Maherali N, Hochedlinger K (2009) Tgfbeta signal inhibition cooperates in the
induction of iPSCs and replaces Sox2 and cMyc. Curr Biol 19: 1718–1723.
18. Ichida JK, Blanchard J, Lam K, Son EY, Chung JE, et al. (2009) A small-
molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by
inducing nanog. Cell Stem Cell 5: 491–503.
19. Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S (2009) Hypoxia
enhances the generation of induced pluripotent stem cells. Cell Stem Cell 5:
237–241.
20. Lagarkova MA, Shutova MV, Bogomazova AN, Vassina EM, Glazov EA, et al.
(2010) Induction of pluripotency in human endothelial cells resets epigenetic
profile on genome scale. Cell Cycle 9: 937–946.
21. Ho PJ, Yen ML, Lin JD, Chen LS, Hu HI, et al. (2010) Endogenous KLF4
expression in human fetal endothelial cells allows for reprogramming to
pluripotency with just OCT3/4 and SOX2. Brief Report. Arterioscler Thromb
Vasc Biol 30: 1905–1907.
22. Zhu S, Li W, Zhou H, Wei W, Ambasudhan R, et al. (2010) Reprogramming of
human primary somatic cells by OCT4 and chemical compounds. Cell Stem
Cell 7: 651–655.
23. Giorgetti A, Montserrat N, Aasen T, Gonzalez F, Rodriguez-Piza I, et al. (2009)
Generation of induced pluripotent stem cells from human cord blood using
OCT4 and SOX2. Cell Stem Cell 5: 353–357.
24. Haase A, Olmer R, Schwanke K, Wunderlich S, Merkert S, et al. (2009)
Generation of induced pluripotent stem cells from human cord blood. Cell Stem
Cell 5: 434–441.
25. Miura K, Okada Y, Aoi T, Okada A, Takahashi K, et al. (2009) Variation in the
safety of induced pluripotent stem cell lines. Nat Biotechnol 27: 743–745.
26. Taylor CJ, Bolton EM, Pocock S, Sharples LD, Pedersen RA, et al. (2005)
Banking on human embryonic stem cells: estimating the number of donor cell
lines needed for HLA matching. Lancet 366: 2019–2025.
27. Nakatsuji N, Nakajima F, Tokunaga K (2008) HLA-haplotype banking and iPS
cells. Nat Biotechnol 26: 739–740.
Reprogramming HUVECs to Pluripotency
PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e19743